Met Met/Met allele showed elevated PPI levels whereas startle reactivity and habituation did not differ from the other two genotypes. These preliminary results imply that PPI is influenced by COMT Val 158 Met genotype in schizophrenia as well. In concert with other findings, our data suggest that PPI is a polygenic trait.
Introduction
Prepulse inhibition (PPI) of the acoustic startle response has been established as an operational measure of sensorimotor gating, and reductions in PPI have been consistently demonstrated in patients with schizophrenia. 1 PPI is defined as a reduction of the startle reflex response that occurs when a loud startle stimulus is preceded by a weak nonstartling stimulus. 2 It was proposed that the mechanism underlying PPI regulates sensory input by filtering out irrelevant or distracting stimuli to prevent sensory information overflow. 3 Human and animal studies suggest that PPI is critically modulated by dopamine neurotransmission at several stages of the cortico-striato-pallidopontine (CSPP) circuitry that has been shown to process PPI. 4, 5 Consequently, it has been postulated that the supposed alterations of dopamine function in schizophrenia may also account for the PPI deficit seen in these patients. 6 Catechol O-methyltransferase (COMT) is a key dopamine catabolic enzyme that presents a significant modulator of prefrontal cortical function, and initially the COMT gene was suggested as a candidate for schizophrenia susceptibility. 7, 8 However, association studies did reveal divergent results, but the Val 158 Met polymorphism seems to have a strong impact at least on cognitive functioning especially in ''prefrontal'' neurocognitive tasks in schizophrenia. 9, 10 Recently, it has been shown that the COMT Val 158 Met polymorphism strongly affects PPI in healthy human volunteers. 11 Individuals homozygous for the Met allele displayed higher PPI levels than Val homozygotes, while heterozygotes were intermediate. This pattern is in line with previous results on the influence of the COMT Val 158 Met polymorphism on executive functioning in healthy individuals and schizophrenia patients. 12 Additionally, it has been shown that PPI is linked with planning and strategy formation in healthy humans. [13] [14] [15] Because we have previously shown that PPI in schizophrenia patients depends on the linked T102C and A-1438G polymorphisms of the serotonin-2A receptor (5-HT 2A R), we reanalyzed our patient sample to investigate also the impact of the COMT Val
158
Met polymorphism on PPI in schizophrenia. 16 Because Roussos et al 11 have shown that healthy homozygous carriers of the Met allele display the highest PPI levels, we predict a comparable pattern in our schizophrenia patients. 
Methods and Materials

Participants
Genotyping
In all patients, DNA for genotyping was isolated either from EDTA-anticoagulated blood or permanent cell cultures received after transforming the lymphocytes with Epstein-Barr virus. The isolation of the DNA followed the QIAGEN protocol for the Blood & Cell Culture DNA Maxi Kit (QIAGEN, Hilden, Germany). Polymerase chain reaction (PCR) was performed using 12.5 ng of DNA. The COMT Val
158
Met polymorphism was analyzed by a Taqman Assay. The procedure followed the protocol for Taqman Assays with the use of Taqman Universal PCR MasterMix, No AmpErase UNG (Applied Biosystems, Foster City, CA). Each assay consists of the unlabeled forward primer and the unlabeled reverse primer and 2 reporters that are dye labeled with FAM and VIC. The assays are designed for allelic discrimination of specific single-nucleotide polymorphisms. All alleles were scored in a single well by measuring the fluorescence at the end of the PCR using a Tecan Ultra 384 reader (Tecan, Crailsheim, Germany). Excitation and emission wavelengths for the FAM-labeled probes were 485 and 535 nm and for the VIC-labeled probes 535 and 590 nm, respectively.
Startle Response Measurement
Our equipment, setup, and standard PPI testing procedures have been described in detail previously. 20, 21 Each examination began with a 4-minute acclimation period of 70-dB background noise that was continued throughout the session. Participants received 73 white noise sound pulses at an intensity of 116 dB (instantaneous rise/fall time) and a duration of 40 milliseconds separated by variable intertrial intervals between 8 and 22 seconds (mean 15 seconds). In 36 of the trials, the pulse was preceded by a 20-millisecond 86-dB white noise prepulse (instantaneous rise/fall time) with an interstimulus interval (ISI) of 120 milliseconds. The initial trial was a pulse-alone (PA) trial, which was separated for further analysis. All following trials were presented in a pseudorandomized order. The entire test session lasted about 20 minutes. To ensure that PPI was not influenced by smoking withdrawal, smoking ad libitum was permitted before testing. 22 Trial exclusion and scoring criteria were identical to those used in previous studies 20, 21 Subjects with error trials >50% were excluded from data analysis. Based on this criterion, 3 patients (4.2%, 1 Met/Met, and 2 Val/Met carriers) were excluded from analysis. 
Statistical Analysis
The mean percent PPI of startle magnitude was calculated using the formula: % PPI = 100 3 (magnitude on PA trials À magnitude on prepulse (PP) trials)/magnitude on PA trials. 23 To assess habituation of startle reactivity, PA trials were divided each in 6 blocks. Startle reactivity was assessed by the mean amplitude of the first block of PA trials and the mean amplitude of all PA trials. The data were analyzed by analysis of variance (ANOVA) with exception of frequency data. Frequency data were analyzed using v 2 tests. Based on significant main effects, Tukey Honest Significance Difference (Tukey-HSD) post-hoc comparisons were performed. Interrelationships between startle measurements and clinical or demographic data were tested using Pearson productmoment-correlation. The confirmatory statistical comparisons were carried out at a significance level set at P < .05 (2 tailed). Within the correlation analyses, the significance level was set at P < .005 (2 tailed) in order to avoid accumulation of a error.
Results
The COMT Val 158
Met genotype frequency was distributed in accordance to the Hardy-Weinberg Equilibrium (HWE; X 2 1 = 1.0, P = .32). Given that the 5-HT 2A T102C, A-1438G, and Y452H genotype frequencies were also distributed in accordance to the HWE in the present sample, genetic inhomogeneity of the analyzed population is unlikely. 16 The groups did not differ regarding demographic and clinical data (see table 1 ).
In contrast to all other startle parameters, PPI was significantly affected by COMT genotype (F 2,65 = 3.05, P < .05, g 2 = 0.09) (see figure 1 for PPI data and table 2 If Met/Met carrier were compared with a merged group of carriers of the Val allele (Val/Met þ Val/Val), both groups significantly differ regarding PPI (F 1,67 = 5.4, P < .05, d = 0.71). Separate analyses of covariance (ANCOVAs) of the 3 genotype groups introducing age, smoking status, medication status, chlorpromazine equivalents, gender, PANSS scores, and startle amplitude as covariates revealed significant or near significant effects for the factor genotype (P = .05-.08, g 2 = 0.08-0.09). An ANCOVA of the PPI data, including genotype and gender as grouping factors, and age, PANSS total score, and chlorpromazine equivalents as covariates, displayed significant main effects of the factors genotype (F 2,56 = 3.21, P < .05, g 2 = 0.10) and the covariate age (F 1,56 = 3.93, P < .05, g 2 = .07). Gender, PANSS total score, and chlorpromazine equivalents did not show a significant impact on PPI and also the interaction of gender and genotype was not significant. For the analysis of the possible impact of COMT genotype on the habituation curves, a repeated-measurement ANOVA (3 groups 3 6 blocks) of the 6 PA blocks was done. This analysis revealed a significant main effect of factor block, reflecting total habituation (F 5,61 = 17.3; P < .001, g 2 = 0.59). The factor group was not significant (F 2,65 = 0.69; P = .51, g 2 = 0.02). Finally, the interaction of the factors block and group was also not significant (F 10,122 = 1.31; P = .23, g 2 = 0.10), indicating a similar progression of habituation in all groups (see figure 2) .
Correlational analysis of startle parameter and patient characteristics within the total sample revealed that the mean amplitude of PA trials was negatively associated with the PANSS positive score (r = À0.37, P = .002) and that the mean amplitude of PA trials in the first block was inversely correlated with the PANSS positive score (r = À0.38, P = .002] and the PANSS total score (r = À0.34, P = .005). These findings indicate that low startling patients displayed more severe psychotic symptoms. PPI did not correlate with any clinical or demographic data.
Discussion
To our knowledge, this is the first study demonstrating that the COMT Val
158
Met polymorphism affects sensorimotor gating in schizophrenia. The present preliminary data are largely in agreement with the recent study of Roussos et al 11 who found similar effects in a sample of male healthy human volunteers. However, these authors found a much stronger effect of the factor COMT genotype (g 2 = 0.25) compared with our results (g 2 = 0.09). This could be explained by the fact that Roussos et al 11 measured a highly homogeneous sample of only male university students, whereas we assessed a heterogeneous patient sample with mixed gender, a broad age distribution, and psychotropic medication. Such moderating effects may also explain why Montag et al 24 did not find an effect of COMT Val
Met on PPI in their sample of healthy female university students. However, this study is not directly comparable to Roussos' and our study because of different stimulus parameters used for prepulse and PA trials. For a detailed discussion of these differences see Roussos et al. 11 Furthermore, Roussos et al 11 reported significant lower PPI levels within homozygous carriers of the Val allele compared with both the Val/Met group and the Met/ Met carriers. In contrast, we only found elevated PPI levels in the Met/Met group, while the Val/Met group and the Val/Val group displayed comparable PPI-levels. The reasons for this may be due either to a smaller sample size, demographic sample differences, an influence of schizophrenia itself, or a medication effect. The last explanation maybe the most likely one because it has been shown that atypical antipsychotics-such as quetiapine or clozapine-increase PPI in subjects with low (but not high) baseline PPI levels. 25, 26 It is therefore conceivable that Val/Val patients (who presumably have the lowest PPI if untreated) received the maximum benefit from medication compared with the other 2 genotype groups.
COMT messenger RNA is much more expressed in the prefrontal cortex and the hippocampus than in the striatum, the ventral tegmental area, or the substantia nigra. 8 Because all these structures take part in the CSPP circuit regulating PPI, it is most likely that the Val 158 Met polymorphism influences PPI at the prefrontal or hippocampal level. 5 However, carriers of the Met allele display a lesser COMT activity compared with Val allele carriers resulting in increased dopamine concentrations especially in the prefrontal cortex of the Met allele carriers. 8 Thus, enhanced prefrontal dopamine concentrations may contribute to the elevated PPI in the Met/Met variants, which would be in line with the observations that reduced dopamine activity in the prefrontal cortex results in a disruption of PPI. [27] [28] [29] However, the impact of COMT Val 158 Met genotype on hippocampal dopamine transmission is less understood so far, and thus, the hippocampus may play also a role in the PPI alterations by COMT Val 158 Met genotype. Currently, other genetic variations have also been reported to have an impact on sensorimotor gating. So it has been shown that the dopamine-D3 receptor Ser 9 Gly polymorphism modulates PPI in healthy humans and that a mutation of the Neuregulin-1 gene also affects PPI in healthy human volunteers as well as in schizophrenia patients. 30, 31 Additionally, we have recently demonstrated that the 5-HT 2A R T102C/A-1438G polymorphisms have a strong impact on PPI in the same sample of schizophrenia patients presented here. 16 In agreement with some animal data, these results in humans support the view that PPI is probably a polygenetic trait. 32 Moreover, in an explorative analysis, COMT Val 158 Met and 5-HT 2A R T102C/A-1438G genotype did not appear to interact regarding PPI in our patient sample (F3,60 = 0.1, P = .94, g 2 = 0.01). Nevertheless, because the power of the present study is too small, any conclusions with regard to epistatic effects on PPI should await replication in larger samples.
The present study has some limitations. First, we only use one prepulse-pulse trial condition (85 dB-120 milliseconds) that may have masked possible stimulus or stimulus by genotype-dependent effects on PPI. However, Roussos et al 11 used several prepulse-pulse conditions, but they could not show any interactions between prepulse intensity, ISI, and COMT genotype. Second, we did not examine a healthy control group. But, in agreement with previous literature, the total group of schizophrenia patients did show significantly decreased PPI levels when compared with equivalent groups of healthy controls (n = 46, 56.9%, standard error of the mean = 3.2), who were assessed with the same startle paradigm in our previous work (t 112 = 3.06; P < .01). 21, 33 Nevertheless, the present findings drawn only from schizophrenia patients replicate and extent the previous results that COMT Val 158 Met genotype affect PPI in healthy human volunteers. Third, we could not rule out medication effects. However, it is impossible to study behavioral genetics only in unmedicated schizophrenia patients because the expectable sample sizes would be insufficient.
In conclusion, the present results tentatively suggest that PPI of schizophrenia patients depends on COMT Val 158 Met polymorphism. In concert with previous human and animal findings showing that PPI is affected by multiple mutations, it is suggested that PPI (like schizophrenia) is modulated by polygenetic factors. Future studies with larger samples of schizophrenia patients and healthy controls are needed to explore the multiple single and epistatic effects of different gene mutations on PPI, which may provide a window into the polygenetic causation of schizophrenia.
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